Inside Semmelweis: Doceree's AI Bet on Pharma Marketing

Doceree launched Semmelweis, an artificial intelligence reasoning and orchestration model built specifically for pharmaceutical commercialization, the company announced.¹ The model underpins Daily Command, Doceree's newly launched commercial operating system for pharma, and the rest of the company's product suite.

According to the healthcare marketing platform, Semmelweis differs from general-purpose AI models in that it is grounded in clinical context rather than the open web, drawing on treatment pathways, care behavior and prescribing intent through what Doceree calls Clinical Intent Signals, or CIS.¹

Harshit Jain, MD, founder and global CEO of Doceree, said the company built Semmelweis to identify prescribing signals early while operating within industry compliance requirements. "We could have shipped a feature and moved on," Jain said in a press release.¹ "We named it instead, because the lesson matters. Semmelweis saw the truth before medicine was ready for it. Our model is built to see the signal early — and to act on it only within the guardrails this industry rightly demands. It is the first model we have named. It will not be the last."

What Is Semmelweis?

Semmelweis is built on top of frontier AI systems for language and reasoning, then layered with proprietary components the company said a general-purpose model cannot replicate, including:¹

• Clinical grounding: The model draws on Doceree's ESPYIAN identity graph of more than 6 million verified health care providers, live Clinical Intent Signals and more than 185 direct electronic health record integrations, according to the company.
• Bounded action space: Semmelweis does not access patient data. The model works only with de-identified, HCP-level context and recommends actions the company said already comply with medical, legal and regulatory guidelines, calling the outputs advisory, human-approved, auditable and designed to be ready for medical, legal and regulatory review.
• Closed measurement loop: Doceree said outcomes the model observes feed back into future recommendations, with the goal of improving precision over time.

Semmelweis reasons behind Daily Command as well as Doceree's Clinical Intent Suite, RepTwin field-agent tool, Co-pay.com and the Doceree Marketplace, according to the company. Doceree said the model is designed to optimize toward filled and refilled prescriptions rather than impressions or claims.

Kamya Elawadhi, co-founder and president of Doceree, said the model is meant to operate invisibly to clients. "Our clients never see the model, they see what it makes possible," Elawadhi said.¹ "Recommendations that arrive grounded in clinical context, human-approved, and ready for MLR, built for the way pharma actually works, not adapted to it. And because one model runs beneath every Doceree product, that standard follows our clients everywhere they work with us."

Why Does Semmelweis Matter for Pharma?

The launch comes as large pharmaceutical companies increase AI investment in commercial operations, not only in research and development.

In remarks on Pfizer's fourth-quarter 2025 earnings call in February, Chairman and CEO Albert Bourla told investors the company is scaling artificial intelligence "across R&D, manufacturing, commercial and patient engagement to improve productivity and accelerate innovation."² Bourla said AI is helping the company "accelerate new product launches, deliver insights for dynamic targeting, and support personalized messaging and real-time marketing content" in its commercial function. Pfizer, like other manufacturers, plans to add more than 1,200 graphics processing units over the next two years to support an AI buildout.²

In May, a coalition of 75 pharmaceutical brand, commercial, and agency executives from major pharmaceutical companies publicly endorsed Doceree’s Daily Command, signaling a shift toward consolidated marketing workflows in pharma.

Doceree said general-purpose AI models cannot distinguish a physician researching a therapy from one who is close to prescribing it, and that Semmelweis is designed to operate within medical, legal and regulatory review requirements from the outset rather than being adapted to them afterward.¹

That distinction points to where the industry's AI dollars are actually headed next: not toward bigger models, but toward narrower ones built to survive legal, medical and regulatory review before they ever touch a physician.

References

1. Doceree. "Doceree Unveils Semmelweis: The First AI Model Purpose-Built for Pharma Commercialization." Press release, July 21, 2026.
2. Pfizer Inc. "Fourth-Quarter 2025 Earnings Conference Call Prepared Remarks." Feb. 3, 2026. https://s206.q4cdn.com/795948973/files/doc_financials/2025/q4/Q4-2025-Earnings-Conference-Call-Prepared-Remarks.pdf